---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015734"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:24:05.187971+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ReShape reports Q3 rev $2.3M (+6.4% YoY); merger with Vyome, asset sale to Biorad for $5.16M

## Summary
- Q3 revenue $2.3M, up 6.4% YoY and 16.6% sequentially; gross margin 62.8%.
- Operating expenses down 40.6% in first 9 months of 2024 vs 2023.
- Merger with Vyome: ReShape stockholders to own ~11.1% of combined company.
- Asset sale to Biorad for $5.16M cash; includes Lap-Band, Obalon, DBSN systems.
- Received Health Canada approval for Lap-Band 2.0 FLEX and $241K NIH grant.

## SEC filing metadata
- accession: 0001558370-24-015734
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000155837024015734/0001558370-24-015734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000155837024015734/rsls-20241114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015734
- JSON: https://secwatch.observer/filing/0001558370-24-015734.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015734.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.